Table 3.
Parameters | Values |
---|---|
Number (%) who received TPE | 97 (100) |
Number (%) who received rituximab before recurrence | 38 (39.2) |
Days to platelet normalization, median (IQR) | 5 (4-7) |
Number of TPE to achieve clinical response, median (IQR) | 4 (3-5.5) |
Outcome, n (%) | |
Remission | 42 (43.3) |
Recurrence | 55 (56.7) |
Exacerbation | 39 (40.2) |
Relapse | 22 (22.7) |
Relapse after exacerbation | 6 (6.2) |